Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
2022 · Journal of Medicinal Chemistry · 566 citations
https://doi.org/10.1021/acs.jmedchem.2c00117
K
Kentaro Uemura
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
1.8K
Citations
19
h-index
30
i10-index
Kentaro Uemura is an academic researcher from Infectious Disease Consultants. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Hepatitis C virus research & Mosquito-borne diseases and control. The author has an h-index of 19, co-authored 64 publications.
ORCID: 0000-0002-0145-566XPapers by this author
worksTMPRSS11D and TMPRSS13 Activate the SARS-CoV-2 Spike Protein
2021 · Viruses · 87 citations
https://doi.org/10.3390/v13030384
MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
2021 · Scientific Reports · 34 citations
https://doi.org/10.1038/s41598-021-84882-7
5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2
2021 · iScience · 17 citations
https://doi.org/10.1016/j.isci.2021.103120
SR-B1 and LDLR have a redundant role in HCV entry.
2016 · Figshare · 0 citations
https://doi.org/10.1371/journal.ppat.1005610.g003
SR-B1, LDLR and VLDLR participate in the binding step of HCV entry.
2016 · Figshare · 0 citations
https://doi.org/10.1371/journal.ppat.1005610.g005
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat